Celltrion (068270) Investor Presentation summary

Business overview

• Plans to commercialize 22 biosimilar products by 2030, targeting diverse therapeutic areas with differentiated formulations and administration routes.

• Entered the US market with Zymfentra and expanded direct sales in the EU and US, strengthening global distribution.

• Owns 250,000L drug substance capacity in Songdo, South Korea, supporting large-scale production.

• 2024 cumulative sales by 3Q exceeded total 2023 sales; annual sales expected to surpass 3.5 trillion KRW guidance.

• OP margin in 3Q24 improved by 15.3 percentage points QoQ, returning to the mid-20% range.

Biosimilar portfolio and global performance

• Aims to commercialize 22 biosimilars by 2030, with a pipeline targeting a combined market size of $182 billion.

• Remsima/Inflectra holds 60% market share in Europe and double the share of competitors in the US.

• Remsima SC achieved 24% market share in EU5, with combined IV+SC share at 76%.

• Truxima maintains ~30% market share in Europe and US; Herzuma holds ~70% in Japan.

• Yuflyma and Vegzelma saw rapid sales growth in Europe, with Yuflyma's 3Q24 sales 1.7x 2023 and Vegzelma's 2.9x.

Novel drug development

• Zymfentra, the first and only subcutaneous infliximab, offers high efficacy and patient convenience, with patent protection until 2037-2040.

• Achieved rapid US market penetration, listed on top 3 PBMs, and supported by strong marketing.

• Zymfentra's prescription and shipment volumes have shown strong monthly growth since launch.

• Innovative pipeline includes ADCs and multi-specific antibodies, with multiple INDs planned for 2025-2028.